
The Radical Reversal in Attitudes About Obesity Medicines
On Friday, the AP-NORC Center for Public Affairs Research documented a remarkable reversal in attitudes about obesity medicines. Roughly half of the public believes “it’s a good idea” to use obesity medicines for obesity or weight-related health conditions. Likewise, most Americans believe Medicare and Medicaid should cover the use of these drugs. Only about 20% of the public says any of this would be a bad idea.
Of course, support for this goes down pretty fast for use of these medicines for people who have neither obesity nor a weight-related health condition. Opinions are split on these medicines for teens with obesity. Favorable sentiment is at 35% while 37% say “it’s a bad idea.”
A Radical Shift
Without a doubt, these findings represent a radical shift in attitudes about obesity medicines from prevailing attitudes of the last decade. In 2013, after the launch of a few new obesity medicines, Andrew Pollack wrote in the New York Times:
“Americans spend tens of billions of dollars each year to lose weight — gym memberships, Weight Watchers and other programs, operations, nutritional supplements and whatever the latest diet fad might be.
“But the first new prescription weight-loss drug to reach the market in 13 years is having a hard time winning even a tiny slice of that huge market, despite an apparent need.”
Back then, Consumer Reports was telling people “you should skip weight loss drugs.” Barely a quarter of primary care physicians agreed with regular use of obesity medicines.
So, yes, we are witnessing a radical shift in public attitudes about obesity medicines. No doubt it has something to do with dramatic gains in effectiveness and proof that their judicious use can extend a person’s life.
Click here and here for reports on this new opinion research.
U-Turn over Caerketton Hill, photograph by Richard Webb, licensed under CC BY-SA 2.0
Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.
February 2, 2025